Anlotinib plus immunotherapy and chemoradiation for high-risk nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a combination of an oral targeted therapy (anlotinib) plus immunotherapy and standard chemoradiation for people with high-risk nasopharyngeal cancer. The goal is to see if this approach is more effective than standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You must have a type of nasopharyngeal cancer called non-keratinizing, at a high-risk stage (T4N2 or T1-4N3).
- You must be in good physical condition (ECOG performance score 0 or 1).
- Your blood counts, liver and kidney function must be within a certain range.
- You cannot have active autoimmune diseases, uncontrolled heart problems, or other cancers (except certain treated ones).
- You cannot be pregnant or breastfeeding, and must use effective contraception if you are of childbearing potential.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a new immunotherapy (QL1706) plus standard chemoradiation for people with advanced nasopharyngeal cancer that hasn't spread to distant organs. The goal is to see if adding this drug helps control the cancer better than standard treatment alone.
This trial tests a combination of an EGFR antibody, a PD-1 inhibitor, and chemotherapy for people with nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this new mix can help shrink tumors or slow the disease.
This trial tests a shorter course of the immunotherapy drug tislelizumab combined with standard chemotherapy and radiation for a specific type of nasopharyngeal cancer. It aims to see if this approach is safe and effective for patients with advanced-stage disease.
This trial tests combining low-dose radiation with an immunotherapy drug (toripalimab) and chemotherapy for people whose nose and throat cancer has come back or spread. The goal is to see if this combination works better than standard treatments.
This trial tests a combination of low-dose radiation, chemotherapy, and immunotherapy for nasopharyngeal cancer that has spread to the liver. It aims to see if this approach can help shrink tumors and improve outcomes.
This trial tests a combination of a new targeted cancer drug (becotatug vedotin), an immunotherapy (PD-1 blockade), and chemoradiotherapy for newly diagnosed advanced nasopharyngeal cancer that has spread to nearby lymph nodes. The goal is to improve outcomes for patients with this aggressive cancer type.
Hear when a new Nasopharyngeal Cancinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.